View Clinical Trial (Medical Research Study)
A Multi-Center, Open-Label Extension Study to Examine the Safety and Tolerability of ACP-103 in the Treatment of Psychosis in Parkinson's Disease
| City: |
|
Scarborough |
| State: |
|
Maine |
| Zip Code: |
|
04074 |
| Conditions: |
|
Parkinson's Disease Psychosis |
| Purpose: |
|
To assess the long-term safety and tolerability of ACP-103 in subjects with Parkinson's
disease psychosis.
|
| Study Summary: |
|
|
| Criteria: |
|
Inclusion Criteria:
- Subject has completed the treatment period of a previous blinded study of
pimavanserin
- The subject is willing and able to provide consent
- Caregiver is willing and able to accompany the subject to all visits
Exclusion Criteria:
- Subject has current evidence of a serious and or unstable cardiovascular,
respiratory, gastrointestinal, renal, hematologic or other medical disorder
- Subject is judged by the Investigator to be inappropriate for the study
|
| NCT ID: |
|
NCT00550238 |
| Primary Contact: |
|
Mary Aloisio
Phone: 858-320-8620
Email: maloisio@acadia-pharm.com
|
| Backup Contact: |
|
N/A |
| Location Contact: |
|
Scarborough, Maine 04074
United States
There is no listed contact information for this specific location.
Site Status: Recruiting |
| Data Source: |
|
ClinicalTrials.gov |
| Date Processed: |
|
June 19, 2013 |
| Modifications to this listing: |
|
Only selected fields are shown, please use the link
below to view all information about this clinical trial. |
|
Click to view Full Listing
|